Why the study?
Does the persistence of guideline-recommended secondary prevention medications decline over 18 months in patients discharged after acute coronary syndrome?
Population
494 patients discharged after acute coronary syndrome treatment from a tertiary hospital in South Korea…
Design
Cohort
Follow-up
18 months
Authors
Loading...
Declining post-ACS persistence of guideline-directed therapy signals need for closer monitoring; leaves open optimal real-world adherence strategies.
Does the persistence of guideline-recommended secondary prevention medications decline over 18 months in patients discharged after acute coronary syndrome?
While the majority of ACS patients receive guideline-recommended secondary prevention medications at discharge, adherence significantly declines over 18 months, highlighting the need for careful monitoring.
Choi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: